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1 Abstract
Phosphoionositide 3-kinase (PI3K) is a family of enzymes that are part of the PI3K
signalling pathway, which is one of the most often altered pathways in human cancer. The
PI3K family is divided into three classes, were the class I produce phosphatidylinositol
(3,4,5)-triphosphate (PIP3), a secondary messenger that acts upon several pathways, and is
linked to cancer. Of the four distinct isoforms of class I PI3K, the p110α, and p110β forms
are ubiquitously expressed in all tissues. Most research has been conducted on p110α, due
to the frequent observations of mutations in cancers. . Less research has been done on
p110β but it has been shown to be exhibit oncogene characteristics when overexpressed.
(Or last sentence: p110β has also been extensively shown to exhibit oncogene activity.)
Our group has observed different resolving patterns when probing western blots with
antibodies targeting other sites of the p110β protein. The focus of this thesis was to
investigate and explain this inconsistency.
During this study, the existence of the theoretical short form of p110β “Q68”, became a
plausible explanation. This theoretical form started from a start codon at amino acid
number 555, and contained an insert of 15 bp, compared to canonical p110β. To validate
the existence of the p110β isoform, the insert was targeted in a RT-PCR experiment. The
theoretical ATG site for the short form was found to have a stronger Kozak sequence then
the canonical ATG. The validity of the Q68’s ATG to function as a start codon was tested
by mutating either the canonical ATG or the short form ATG. Then expressing these
mutants and observing if the associated bands of each inform was present or not.
In addition, during this thesis, Q68 was found to exhibit autophagy like patterning when
overexpressed, tagged to EGFP.
p110β has been implicated in autophagy, but these studies are controversial, the possible




Phosphoionositide 3-kinase (PI3K) is a family of kinases that produce
polyphosphoinositides (PPIns); signalling molecules that are involved in a wide array of
signalling pathways, by phosphorylation. These kinases have seen a large amount of focus
over the last few years. This is mainly due to their direct involvement in human disorders,
such as cancer and diabetes mellitus type 2. The kinases are part of the PI3K pathway,
which regulates the levels of different PPIns.
2.1.1 Phosphatidylinositol, and its phosphorylated derivatives.
Phosphatidylinositols (PtdInss) is a glycerophospholipid that accounts for about 10-15% of
all membrane phospholipids (Viaud et al. 2016). It consists of an inositol head group,
mounted to a glycerol backbone through a phosphodiester bond. Two hydrophobic acyl
chains are connected on the glycerol backbone (Figure 2.1). Phosphorylation can be done
on the 3′, 4′, and 5′ hydroxyl groups in the inositol ring, each permutation making one of
the seven PPIns. Phosphorylation of the 2′, and 6′ is hindered, likely by steric hindrance
(Viaud et al. 2016).
Figure 2.1: Structural diagram of phosphatidylinositol. The inositol headgroup is on
the left with each hydroxyl group numbered. It is connected to the glycerol backbone with
a phosphodiester bond. With ester bonds connecting the hydrophobic fatty acid chains
(C18:0/C20:4) to the glycerol. Different PI3K can phosphorylate the hydroxyl groups on
the 3′ positions.
The PPIns are categorised into three groups: the mono-phosphorylated (PtdIns3P,
PtdIns4P, and PtdIns5P), the di-phosphorylated (PtdIns(3,4)P2, PtdIns(3,5)P2, and
PtdIns(4,5)P2), and one tri-phosphorylated (PtdIns(3,4,5)P3). Distribution between these
PPIns, and the PtdIns is not equal, with 80% of the total population being the
non-phosphorylated PtdIns; with PtdIns4P, and PtdIns(4,5)P2 making up about 10%, and
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the remaining forms not representing more than 1-2% of the total PPIn population (Viaud
et al. 2016).
These lipids function as secondary messengers for several different cellular processes. These
include, but are not limited to autophagy, intracellular trafficking, cytokinesis,
autophagosome maturation, cell survival, proliferation and motility. They can directly
interact with protein domains such as PH (Plekstrin Homology), FYVE (Fab-1, YGL023,
Vps27, and EEA1), PX (phox) or the ENTH (Epsin N-Terminal Homology) domains. The
synthesis of PPIns is activated or inhibited by a variety of stimuli (Hormones, growth
factors, adhesion molecules, chemoattractants, stresses, etc.), in order to create membrane
territories, containing specific PPIns that then recruit specific signalling proteins to control
different cellular events (Viaud et al. 2016).
2.1.2 PI3K’s, and the PI3K pathway
Phosphorylation of the 3′ OH groups on the inositol headgroup of PtdIns and PPIns is done
by the kinases in the PI3K family (Vanhaesebroeck and Waterfield 1999). This family is
divided into three classes: I, II, and III. Class I consists of a group of heterodimers, made
up of a catalytic subunit, and a regulatory subunit. Class I PI3Ks produce the
tri-phosphorylated phosphatidylinositol (3,4,5)-triphosphate (PIP3) from their substrate
phosphatidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2) (Figure 2.2). Class I is further
divided into Class IA, and IB. Class IA consists of the catalytic subunits: p110α, encoded
by the gene PIK3CA; p110β, PIK3CB ; and p110δ, by PIK3CD. The regulatory subunits
are p85α, p55α, and p50α, encoded by PIK3R1 ; p85β, PIK3R2 ; p55γ, PIK3R3 ; and p87,
by PIK3R6. Class IB only consists of the catalytic subunit p110γ encoded by PIK3CG ;
and its regulatory subunit p101, by the PIK3R5 gene. The p110αand p110β isoforms of
PIK3 are expressed in all tissues, with p110γ, and p110δ only being found in immune cells
(Vanhaesebroeck and Waterfield 1999, and Jean and Kiger 2014).
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Figure 2.2: Model of PI3K, and PTEN reactions on PtdIns(4,5)P2, and PIP3.
Model depicting the relationship between PI3K, and PTEN on PIP3, and PtdIns(4,5)P2,
with arrows indicating the catalytic direction. The names p85, and p110 can be substituted
for any of the other class I catalytic, and regulatory subunits.
As the class I PI3Ks are the main focus of this thesis class II, and III will be discussed in
less detail. Class II are monomers that produce the mono-phosphorylated
phosphatidylinositol 3-phosphate (PI3P), from PtdIns, and the di-phosphorylated
PtdIns(3,4)P2 from PtdIns4P. This class consists of three known catalytic isoforms: C2α,
encoded by PIK3C2A; C2β, PIK3C2B ; and C2γ, PIK3C2G. (Posor, Eichhorn-Grünig, and
Haucke 2015, and Jean and Kiger 2014). Class III are heterodimers only known to produce
PtdIns3P from PtdIns. (Leevers, Vanhaesebroeck, and Waterfield 1999). The heterodimer
consists of the catalytic unit vacuolar protein sorting 34 (Vps34), encoded by PIK3C3 ; and
its corresponding regulatory unit vps15, encoded by PIK3R4 (Backer 2008, and Jean and
Kiger 2014). One of the primary functions of the Vps34/Vps15 complex is to promote
autophagy (Jaber and Zong 2013, and Kihara et al. 2001). An activator of the
Vps34/Vps15 complex is Rab5, a small GTPase. It has been found that p85α can bind to
Rab5 and inhibits its activity (Chamberlain et al. 2004).
The PI3K pathway is a part of the more extensive PI3K/Akt/mTOR pathway. This
pathway is initiated by binding between PIP3 and Akt. PIP3 binding to Akt activates it
and increases cell differentiation, cell growth, survival, and proliferation. Phosphorylation
of Akt is done by phosphoinositide-dependent protein kinase 1 (PDK1), and mammalian
target of rapamycin (mTOR) complex 2 (Sarbassov et al. 2005).
Inhibition of PIP3 is mainly regulated by Phosphatase and tensin homolog deleted on
chromosome ten (named so due to frequently being lost from a region of chromosome 10q23
in a variety of human tumours (Li et al. 1997, Steck et al. 1997)) (PTEN) by
dephosphorylating of PIP3, back to PtdIns(4,5)P2 (Figure 2.2); making it a direct
antagonist to class I PI3K, negatively regulating PIP3 production. PTEN is a
well-established tumour suppressor (Hopkins et al. 2014).
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2.1.3 p110α, and p110β history, and main properties
The two ubiquitously expressed class IA PI3Ks (p110α, and p110β) were discovered around
the same time. (p110β) was discovered in 1993, only a year after p110α was established as
a PI3K (Hiles et al. 1992, and Hu et al. 1993). Translated from different genes PIK3CA,
and PIK3CB, and their individual mouse KO are embryonically lethal (Bi, Okabe, Bernard,
Wynshaw-Boris, et al. 1999, and Bi, Okabe, Bernard, and Nussbaum 2002). Even though
these proteins were first described as PI3K virtually at the same time, the knowledge base
for these proteins has since become disproportionate, with p110α having received the most
attention from the scientific community. The main cause of this is that p110α is often
mutated in cancer, while p110β is not (Zhao and Vogt 2008). This is discussed further in
section 2.3.
The two ubiquitously expressed class IA PI3Ks (p110α, and p110β) both contain the same
domains (Figure 2.3). However the functions of some of these domains differ between some
of the domains on these two proteins.
Figure 2.3: A schematic model of both the p110αand p110β proteins. The
proteins are shown with numbered AA’s from N-terminal to N-terminal for localisation of
each domain. With the possible nuclear localisation signal (NLS) of p110βs localisation
denoted in the C2 domain. Abbreviations: ABD - Adaptor Binding Domain, RBD - Ras
Binding Domain.
The adaptor binding domain (ABD) is an N-terminal domain that functions as the binding
site between the catalytic unit, and its regulatory subunit. The p85 subunit binds to p110
predominantly with a coiled-coil region, sandwiched between two SH2 domains, called the
inter-SH2 domain. This binding is further stabilised by interactions with the catalytic
subunits’ helical, C2, and catalytic domains, to the regulatory unit. This binding stabilizes
p110, by so far unknown mechanism(s), and inhibits its catalytic activity. The inhibition
can be hindered, when p85 is bound to receptor tyrosine kinases (RTKs), by disturbing the
interactions of p85 on the helical, C2, and catalytic domains of the catalytic subunit
(Rodriguez-Viciana et al. 1996, and Burke and Williams 2015).
The ras binding domain (RBD) binds to the activators for class I PI3Ks, that act together
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with the RTK signal on p85. For p110α these are RAS GTPase’s. Interestingly p110β does
not bind to RAS, but instead to proteins in the Rho subfamily of small GTPases (Fritsch
et al. 2013). The C2 domain functions as a membrane targeting domain; binding to
phospholipids, and regulates the localisation of the protein within the cell (Farah and
Sossin 2012). Note that p110β has had proof of a NLS within this domain (Kumar et al.
2011). The helical domain is conserved among all the PI3Ks. Its role is not well
understood, but it is likely involved in substrate presentation (PIK helical domain -
PRU00878 2020). Lastly, the catalytic domain is a C-terminal catalytic domain,
responsible for phosphorylation of PtdIns(4,5)P2 to PIP3.
The core downstream signalling is the same for all of the class I PI3Ks, those being Akt
activation, Tec family tyrosine kinases, and guanine nucleotide exchange factors for small
GTPases in the Rho and Arf families. Additionally, some downstream signalling pathways
have been described that are p110β specific for the PI3K family (Bresnick and Backer
2019). Those pathways are “vesicular trafficking in the endocytic and autophagic systems”
(Ciraolo et al. 2008, Jia et al. 2008, Dou, Chattopadhyay, et al. 2010, and Dou, Pan, et al.
2013); also several nuclear functions have been described for p110β. The nuclear functions
that have been described for p110β so far are DNA repair and replication, and nuclear
envelope maintenance, as well as chromosome segregation during mitosis (Kumar et al.
2011, Marqués et al. 2009, and Redondo-Muñoz, Josefa Rodŕıguez, et al. 2013,
Redondo-Muñoz, Pérez-Garćıa, et al. 2015, and Silió, Redondo-Muñoz, and Carrera 2012).
For this thesis, its involvement in cancer, and autophagy are most central. Its connection in
cancer development has been known about the longest. In fact, the discovery of the gene
itself was directly tied to its binding to p85, and its sequence identity with p110α, resulting
in this function of the protein being devised of at the same time as its discovery (Hu et al.
1993).
2.1.4 p110β, and autophagy
Autophagy is a membrane trafficking process that removes and recycles cellular
components. Intracellular components are shuttled into the autophagosome, a bi-layered
vacuole that fuses with a lysosome, containing a cocktail of enzymes that break down the
contents of the autophagosome. This mechanism protects organisms against an array of
pathologies, such as infections, cancer, neurodegeneration, ageing, and heart disease (Levine
and Yuan 2005, Levine and Kroemer 2008). The initiation of autophagy in metazoans is
regulated by PIP3, and PI3P, produced by the class I, and class III PI3Ks (Viaud et al.
2016, Dou, Pan, et al. 2013). PIP3 induces conformational changes in Akt, and this makes
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it possible for other proteins to activate Akt, which will then, among other effects, inhibit
autophagy (Huang et al. 2011). While PI3P initiates it. It was therefore recognised that
class IA PI3Ks inhibited, while the class III PI3K, Vps34/Vps15, activated autophagy.
However it has been found that p110β can function as a positive regulator of autophagy,
independent of its catalytic activity (Dou, Chattopadhyay, et al. 2010).
In studies from Dou, Pan, et al. they describe the mechanism for how p110β is involved in
autophagy. They found that p110β will, when the availability of growth factors becomes
low, disassociate from its growth factor receptor signalling molecules, and instead bind to
Rab5. This protects Rab5 from inhibiting signals and allows it to bind to the Vps34/Vps15
complex, and activate it (Dou, Chattopadhyay, et al. 2010, and Dou, Pan, et al. 2013).
Prior to these studies, the only known mechanism for initiating autophagy was based on
nutrient availability. However, they discovered that the p110β mediated mechanism was
dependent on growth factors instead, not the direct availability of nutrients (Dou, Pan,
et al. 2013). As cells of higher order-multicellular life are often in nutrient-rich
environments (Lum, DeBerardinis, and Thompson 2005), the ability to control autophagy
despite the surrounding nutrient levels is a valuable control mechanism.
Of note is that the studies by Dou, Chattopadhyay, et al., and Dou, Pan, et al., are
problematic for three reasons (Bresnick and Backer 2019). One: overexpression of active
Rab5 could enhance autophagy independently of p110β, as Rab5 has been shown to inhibit
the mTOR complex 1 (Flinn et al. 2010). Two: Rab5 has been shown to be expressed at
150 times more then p110β in vivo, (Schwanhäusser et al. 2011). p110β is therefore
unlikely to have a noticeable effect on Rab5. Three: parts of the argument by Dou, Pan,
et al., and relies on p85 being a Rab5 GAP, i.e. having a downregulating effect on the
protein. This is not replicative under normal conditions; the only studies showing this
connection between p85, and Rab5, have been done with p85 at 50 times the normal
concentration (Dou, Pan, et al. 2013).
2.2 Nuclear PPIn, and p110β
2.2.1 Nuclear PPIn
The cytoplasmic roles of PPIn are well studied, the nuclear roles, however, are less
understood. A significant reason for this is that while the nuclear localisation of PPIns was
discovered in the 1980-90s (Cocco et al. 1987, Payrastre et al. 1992), their importance has
only recently more evident (Fiume et al. 2019, Jacobsen et al. 2019). Independent nuclear
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metabolism and signalling have also been observed. In fact, except for PtdIns(3,5)P2, all
PPIns have been detected in the nucleus (Lachyankar et al. 2000).
Multiple nuclear processes have been identified for PPin; mRNA processing, splicing and
export, chromatin remodelling, transcription, and cell cycle progression (Davis, Lehmann,
and Li 2015; Hamann and Blind 2018; Irvine 2003, Martelli et al. 2011; Musille, Kohn, and
Ortlund 2013; Okada and Ye 2009; and Viiri, Mäki, and Lohi 2012). Nuclear PPIns have
been found to interact with these processes mostly through interaction via polybasic regions
(PBR), also called K/R rich motifs, but also in some cases through PH domains. The
nuclear function of PIP3 is still largely unknown. While some PIP3 binding proteins have
been identified within the nucleus, the function of how these proteins interact with PIP3 is
still not understood (Gavgani, Morovicz, et al. 2020).
2.2.2 Nuclear PIP3 and p110β
Even though the function of nuclear PIP3 is largely unknown, its presence, production, and
breakdown are supported within the nucleus. A pool of PtdIns(4,5)P2: PIP3’s precursor,
has been observed (Osborne et al. 2001, Watt et al. 2002). The kinases that produce
PtdIns(4,5)P2 has been observed in the nucleus. p110β has also been observed in the
nucleus, accounting for the production of PIP3 (Kumar et al. 2011). In addition, the
phosphatase PTEN, has also been observed within the nucleus (Gavgani, Morovicz, et al.
2020). These and additional findings all show that the cellular machinery necessary for the
production, and regulation of PIP3 is present within the nucleus.
Of the ubiquitously expressed class I PI3Ks, only p110β has been found to have a nuclear
localisation. Meanwhile, the structural features that determine p110β nuclear localisation
remain largely unknown. The p85β and a possible NLS in the C2 domain of p110β have
been found to mediate its nuclear localisation (Kumar et al. 2011). Of note is that it is only
the p85β regulatory subunit which facilitates this localisation, suggesting a possible control
mechanism for nuclear localisation of p110β.
Interestingly our group has also shown that p110β has a nucleolar localisation. This
suggests that p110β has a nucleolar role for the PI3K pathway that may contribute to
tumour progression in endometrial cancer (Karlsson et al. 2016; and Gavgani, Karlsson,
et al. 2019).
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2.3 p110β and cancer
The PI3K pathway under normal circumstances is involved in cell differentiation, growth,
survival; and proliferation (Viaud et al. 2016). All three of those points are involved in the
hallmarks of cancer (Hanahan and Weinberg 2000, and Hanahan and Weinberg 2011). In
fact, alterations to the PI3K pathway has been shown to lead to tumourigenesis and
resistance to anticancer therapy (Yang et al. 2019). The hallmarks of cancer are a set of ten
requirements for a cell to become cancerous, proposed by Hanahan and Weinberg. The
requirements include; promote/sustain cell proliferation, migration, glucose transport and
anabolism, cytoskeletal rearrangements, and angiogenesis. All ten points do not necessarily
need to be fulfilled for a cell to become cancerous, although, most cancers observed, fulfil
them all (Hanahan and Weinberg 2000, and Hanahan and Weinberg 2011).
The PI3K pathway is deregulated through several avenues: mutation or amplification of
PI3K, activation of growth factor receptors, or oncogenes upstream of the pathway, or by
loss or inactivation of PTEN (Yang et al. 2019).
The PI3K antagonist; PTEN is often mutated in cancers. Indeed it was discovered, and
named, because of it (Steck et al. 1997). PTEN is regarded as a tumour suppressor gene. A
statement supported by how loss or inactivation of PTEN is observed frequently, and in a
wide array of cancers, including brain, breast, and prostrate cancer. (Yang et al. 2019).
Interestingly it has been found that the inactivation of p110β, not the p110α PI3K isoform
had a lessening effect on the prostate-cancer loss of PTEN phenotype for mice (Jia et al.
2008, and Berenjeno et al. 2012). It would therefore seem that at least prostrate cancer
cells, rely more on p110β, than p110α for malignancy.
This is surprising as most cancerous mutations concerning PI3K, are found on p110α, not
p110β (or p110γ, p110δ). Indeed about 30% of all carcinomas contain some mutation to
the PIK3CA gene (Zhao and Vogt 2008). Upregulation of p110α activity has been shown to
promote cell proliferation, migration, glucose transport and catabolism, cytoskeletal
rearrangements, and angiogenesis (Yang et al. 2019, Fruman and Rommel 2014), all
hallmarks of cancer development (except cytoskeletal rearrangement) (Hanahan and
Weinberg 2000, Hanahan and Weinberg 2011, and Cosmic 2020). Giving p110α a vital role
in the initiation, progression, and maintenance of cancer, as only a few mutations on p110α
can fulfil several requirements for malignancy, and cancer.
Mutations in the PIK3CB gene, on the other hand, are rare. p110β is still involved in
malignancy via other mechanisms. For example overexpression of p110β in its WT form
have been shown to induce an oncogenic phenotype (Aoki et al. 2000, and Kang, Bader,
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and Vogt 2005), in for example prostate, glioblastoma, and endometrial cancer (Thorpe,
Yuzugullu, and Zhao 2015, and Karlsson et al. 2016). In addition it has been shown that
p110β plays an important role in prostate, and breast cancer (Hill et al. 2010, and Dbouk
et al. 2013). The mechanisms of how p110β is activated in cancer, and how it contributes
to cancer development are not well understood (Yang et al. 2019).
Even though mutations on p110β are rare, several activating mutations have been reported
(Bresnick and Backer 2019), such as the glutamic acid substitution to lysine on amino acid
number 633 (E633K). This mutation, located in the helical domain, was first reported in the
same cancer type as the co-inhibition study was conducted on, HER2-positive breast cancer
(Kan et al. 2010). Interestingly this mutation showed a 150% catalytic effect compared to
WT p110β when not in the presence of its regulatory unit. However, in the presence of p85,
it had an equal catalytic effect as WT p110β in vitro. In contrast, when stably expressed in
vivo, the expression was again higher for the E633K mutant. An increased association
between p110β and the membrane may explain the increased activation caused by E633K.
(Dbouk et al. 2013). In advanced prostate cancer, several p110α homologous mutations
have been observed (Robinson et al. 2015). The D1067V activating mutation, located
within the catalytic domain, has also been documented several times (Chang et al. 2016,
Nakanishi et al. 2016, Pazarentzos et al. 2016, and Lasota et al. 2019).
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2.4 Aims
The PI3K pathway is one of the most important pathways with regards to tumour
development, and it is pivotal in several other cellular processes as well. The PIP3
producing kinase p110β is not well understood when compared to the isoform p110α. In
contrast to p110α, the p110β isoform was proven to not only be expressed in the cytoplasm
but also the nucleus (Kumar et al. 2011). Our lab has also shown this localisation in a
panel of endometrial cancer cell lines, including RL95-2, using an antibody raised against
the N-terminal region of p110β (Gavgani, Karlsson, et al. 2019). Unexpectedly the
resolving pattern was found to differ when using antibodies raised more towards the
C-terminal end of the protein; showing additional bands in the nuclear fraction by western
immunoblotting (Abcam, AA: 400-500; and Thermo Fisher, AA: 411-605) (unpublished
data). This inconsistency suggested the existence of a possible additional isoform of p110β.
This thesis aimed to explore the possible existence of an additional p110β isoform, and to
glean some of its possible functions, with the following aims:
• To determine the existence of a short p110β form.
• To clone the shorter p110β form, and determine its subcellular localisation.


















30% Acrylamide/Bisacrylamide BioRad 161-
0158




Calcium chloride CaCl2 Merck 1.02083






Ethidium Bromide EtBr Sigma-
Aldrichr
E1510
Isopropanol IPS Kemetyl 600079
LB Agar MBG Sigma-
Aldrichr
L2897
Magnesium Chloride MgCl2 ANG Merck 1.05833



















Table 3.2: Antibodies used in Western Immunoblotting, and dilutions
WB - Western Blotting
Antibody Supplier Catalogue # Species Dilution
α-Tubulin Santa Cruz 8035 Mouse 1:20’000 WB
Lamin - A/C Santa Cruz 376248 Mouse 1:10’000 WB
Mouse IgG HRP Thermo Fisher 21040 Goat 1:10’000 WB
Rabbit IgG HRP Thermo Fisher 21234 Goat 1:10’000 WB
p110β (C-8) Santa Cruz 376641 Mouse 1:500 WB
p110β (1H9L37) Thermo Fisher 703364 Rabbit 1:250 WB





Dulbecco’s Modified Eagles’s Medium - high
glucose
DMEM Sigma-Aldreichr D6429
Bovine Serum Albumin BSA SigmaAldrichr A7906
100× Penicillin-Streptomycin P/S Merck TMS-AB2-
C
Trypsin-EDTA Trypsin Sigma-Aldreichr T4049







Foetal Bovine Serum FBS Sigma-Aldreichr f7524
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Table 3.4: Cell lines and Bacteria
Name Description Supplier
KLE Human endometrium adenocarcinoma cells Prof. HB Salvesen, Women’s
hospital, UIB
MFE Human endometrium adenocarcinoma cells Prof. HB Salvesen, Women’s
hospital, UIB
RL95-2 Human endometrial carcinoma cells Prof. HB Salvesen, Women’s
hospital, UIB
HAP1 Near haploid human chronic myelogenous
leukaemia cells
Dr H. Aksnes, UIB
HEK
293
Human embryonic kidney cells Prof. M Ziegler, UIB
XL1-
Blue
Supercompetent Cells (QuickChange) Agilent
Table 3.5: Equipment













ND-1000 DNA, and protein
concentration
measurement
Gel Doc™ EZ BioRad ImageLab Agarose imaging





Sonication bath VWR Sonication
Leica DMI6000 B Leica Leica Application Suite Fluorescent cell imaging
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Table 3.6: Primers








































































Table 3.7: Kits, and reagents
Name Supplier Use
Lipofectamine™ 3000 Reagent Thermo Fisher Transfection




NucleoSpinr Gel and PCR Clean-up Macherey-Nagel Plasmid
purification
NucleoSpinr Plasmid Macherey-Nagel Miniprep
SuperSignalr West Femto Maximum
Sensitivity Chemiluminescence
Thermo Fisher Western Blot
Visualisation
SuperSignalr West Pico Chemiluminescence Thermo Fisher Western Blot
Visualisation
NucleoSpinr Plasmid Macherey-Nagel Miniprep
NucleoSpinr Gel and PCR Clean-up Macherey-Nagel Plasmid
purification
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3.1.1 Agarose gel electrophoresis
1× TAE Buffer
40 mM Tris
1 mM EDTA pH 8.0
20 mM Acetic acid





35 g/L LB Broth (Lennox; Sigma Aldrich)
15 g/L Agar
10 g/L Tryptone
5 g/L Yeast extract
5 g/L NaCl
LB medium
20g/L LB Broth (Lennox; Sigma Aldrich)
10 g/L Tryptone
10 g/L NaCl
5 g/L Yeast extract
Super Optimal Broth (SOC) medium
20 g/L Tryptone





2.5 mM g/L KCl
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3.1.3 SDS-PAGE and Western Blotting
Resolving gel
8-12% acrylamide/bisacrylamide (37.5:1)











50mM Tris pH 7.5
150mM NaCl
0.05% Tween20 (100%)
Blocking buffer (Western Blot)


























Cell lines were grown, and cultivated in Dulbecco’s Modified Eagles’ Medium (DMEM),
with 10% fetal bovine serum (FBS), and 1% penicillin-streptomycin (P/S). Cells were
cultured in 10 cm round cell culture dishes, at 37℃ with 5% CO2. Work was conducted in a
laminar flow bench.
4.1.2 Passaging
Cells were passaged when reaching 90% confluency. Media was removed, the cells were then
washed once with PBS pH 7.4. Then trypsinized with 1 ml 0.25% Trypsin for 10 cm plate
(2 ml for 15 cm plate) in an incubator (37℃ with 5% CO2) for approx 5 min until cells were
lifted off by tapping the plate. 10 ml 37℃ DMEM was then added, and cells were
resuspended and split to new plates.
4.1.3 Freezing
Cells were trypsinized as under 4.1.2. Suspended cells were centrifuged for 4 min at 900
rpm, then resuspended in 90% complete DMEM, and 10% Dimethyl Sulfoxide (DMSO).
Cells were put in a CryoPure freezing tube, stored at −20℃ for 1 h before moving to −80℃
for max one week before being moved to liquid nitrogen.
4.1.4 Thawing
Cells were thawed completely in a 37℃ water bath after retrieval from liquid nitrogen. 6 ml
37℃ complete DMEM was added before centrifugation for 5 min at 900 rpm. Cells were
resuspended in 10 ml 37℃ complete DMEM, then plated, and incubated as under 4.1.1.
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4.1.5 Transfection
Foreign DNA was introduced into eukaryotic cells using Lipofectamine 3000 (Table 3.7).
Lipofectamine works by forming liposomes, entrapping DNA, and allowing the DNA to
enter cell membranes.
The cells were grown to approximately 80% confluency in appropriate sized dishes (6-well
or 10 cm plates) (if for immunostaining they contained two coverslips). The medium was
before transfection changed to P/S free DMEM; the cells were kept at 37℃ until the
transfection solution was added. Lipofectamine 3000, and P3000 were diluted in
Opti-MEMr Reduced-Serum Medium (Opti-MEM) according to Table 4.1. The plasmid
was then added to P3000 dilute, and mixed. The P3000/DNA dilute was then added to
each their own lipofectamine dilute, and incubated for 15 minutes at RT to let the
DNA-lipofectamine complexes to form.
Table 4.1: Reagents used during transfection.
Dish size 6-well 10 cm
Opti-MEM 125 µl 250 µl
P3000 4 µl 20 µl
Plasmid 2 µg 10 µg
Lipofectamine 3000 3 µl 24 µl
Each mix was then added dropwise to an appropriate dish. The cells were then left to
incubate for 24-48 h. After incubation they were either fixated and then immunolabeled as
under section 4.1.6) or a whole cell extract was prepared as in section 4.1.7.
4.1.6 Immunolabelling
Cells were plated on coverslips placed in 6-well plates. The transfection was then carried
out as in section 4.1.5. Cells were then fixed with 3.7% paraformaldehyde (PFA) in PBS for
10 min 24-48 hours after transfection. PFA was then removed, and the slips were then
washed 3× with PBS. Cells were then permeabilised by incubation with 0.25% Triton-X100
in PBS for 10 min.
After permeabilization cells were blocked by incubating with 60 µL blocking buffer (5-10%
Goat Serum diluted in 0.1% 2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol
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(Triton-X100)/PBS) for 1 h. The slips were then incubated with primary antibody diluted
(Table 3.2) in blocking buffer for 1 h at RT. They were then washed 4×5 min with PBS,
before incubating with secondary antibody diluted (Table 3.2) in blocking buffer for 1h at
RT.
Slips were then washed three times with PBS for 5 min. The slips were dipped in fresh
Milli Q, drained, and then mounted on freshly cleaned glass coverslips with ProLong™
Glass Antifade Mountant with NucBlue™ Stain (NucBlue mounting medium). Slips were
incubated at RT for 10 min, before being put in storage (4℃, dark).
Subsequent imaging was conducted using a Leica DMI6000 B microscope (Table 3.5).
4.1.7 Whole cell extraction
80% confluent cells grown on 10 cm plates were washed with PBS, before scraping with 0.5
ml radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris, 5 mM EDTA, 1.0%
nonylphenylpolyethylene glycol (Igepal), 0.5% Sodium deoxycholate, 0.1% sodium dodecyl
sulfate (SDS)) (RIPA). The cells were then collected and incubated on ice for 15 min. The
lysate was then sonicated 3×5 sec in 1 min intervals, before centrifuging for 5 min at
13000× g, and 4℃. The supernatant was collected as whole cell extracted, and stored at
−80℃.
4.1.8 Cytoplasmic, and nuclear fractionation
All steps during the fractionation were done on ice, using ice-cold buffers, tubes, and
syringes used. Cells were grown in a 15 cm dish to approximately 80% confluency, then
washed 2× with PBS. The cells were then washed briefly with 10 mM Tris pH 7.8, in order
to remove salt from PBS. Before being scraped with hypotonic buffer ( 10 mM
tris(hydroxymethyl)aminomethane (Tris) pH 7.8, 1.0% Igepal, 1 mM dithiothreitol (DTT),
1:100 mammalian protease inhibitor cocktail, and 2 mM Na3VO4). The cells were collected
and incubated on ice for 3 min. Equal volume ddH2O was added to the lysate, before
incubating for another 3 min. Cells were then sheared 8× through a 23-gauge syringe,
before being centrifuged at 1 000× g at 4℃ for 6 min. The supernatant containing the
cytoplasmic fraction was centrifuged an additional time at 1 000× g at 4℃ for 6 min to
remove nuclear contamination. The supernatant was then stored at -80℃.
The nuclear pellet was re-suspended in 1 ml Washing buffer ( 10 mM Tris pH 7.5, and 2
22
mM MgCl2). Resuspended pellets from RL95-2 cells were sheared again 8× through a
23-gauge syringe to remove cytoplasmic components left. The fraction was centrifuged at 1
000× g at 4℃ for 6 min. The supernatant was removed, and the pellet was resuspended
using 100 µl RIPA ( 50 mM Tris pH 8.0, 0.5% deoxycholic acid, 150 mM NaCl, 1.0% Igepal,
0.1% SDS, 2 mM Na3VO4, and 1× Protease Inhibitor Cocktail) . The nuclear fraction was
then vortexed for 1 min, at full speed, then sonicated in a sonication bath for 2 min. The
fraction was then centrifuged one last time at 16’200× g, at 4℃ for 6 min. The supernatant
was collected as a nuclear fraction, and stored at -80℃.
4.2 PCR techniques
Polymerase chain reaction (PCR) is a flexible and well-established method. Its primary use
is to make large copy number of short DNA sequences. PCR was used for varying uses in
this thesis: reverse-transcription polymerase chain reaction (RT-PCR), cloning, site
directed mutagenesis (SDM), and sequencing.
4.2.1 RT-PCR
RT-PCR is a PCR technique that, among other uses, allows one to detect RNA present
within the cell. It works by first reverse transcribing RNA into complementary DNA
(cDNA). Both RNA extraction and cDNA synthesis was already conducted by another lab
member (Appendix: 6.5, 6.6).
The cDNA sample was used in a PCR together with one of the forward primers targeting
the Q68 insert “Forward Insert 7591/7495/8001”, and the reverse primer “Reverse
sequencing primer” (see table 3.6). This PCR was run using the Phusion High-Fidelity kit
(Table 3.7). Each PCR was run in 50 µl volume with 100 ng cDNA template, 0.1 µM
Forward primer, 0.1 µM Reverse primer, 1 mM MgCl2, 2.5% DMSO, 0.2 mM dNTP, HF
buffer (1.5 mM MgCl2), and 2.0 U Phusion (polymerase). The PCR was then run, as stated
in table 4.2. A sample of each PCR reaction conducted was subsequently run through a 1%
agarose gel as in section 4.5.
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Table 4.2: Thermal program for RT-PCR.
Temperature (℃) Time (mm:ss) Cycles
1st Denature 98 5:00
Denature 98 0:10
Anneal 48 0:30 ×42
Extension 72 0:10
Last extension 72 7:00
Hold 10 ∞
In order to sequence the PCR product, any visible bands of approximately correct resolving
pattern were extracted as described in section 4.5.1.
4.2.2 Cloning
The restriction sites Eco-RI, and XhoI; and the Kozak sequence present in WT p110β was
added to an open reading frame (ORF) p110β, using the Forward EcoRI pcDNA 110β, and
Reverse EcoRI pcDNA p110β(Table 3.8). The PCR was run with 1.0 ng DNA template,
0.1 µM Forward primer, 0.1 µM Reverse primer, 1 mM MgCl2, 2.5% DMSO, 0.2 mM
dNTP, 1× HF buffer (1.5 mM MgCl2), and 2.0 U Phusion (polymerase). The PCR was
then conducted as in table 4.3.
An ORF sequence corresponding to the Q68 was cloned into a pEGFP-C1 vector, to
generate the Q68-EGFP fusion protein tagged at the N-terminus. The PCR was carried out
as above, but with the forward XhoI Q68, and reverse EcoRI Q68 primers instead.
Table 4.3: Thermal program for cloning PCR.
Temperature (℃) Time (mm:ss) Cycles
1st Denature 98 2:00
Denature 98 0:10
Anneal 55 0:30 ×35
Extension 72 2:00
Last extension 72 7:00
Hold 10 ∞
The cloning PCR product was then purified by column purification, using the NucleoSpinr
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Gel and PCR Clean-up kit (Table 3.7), then fused to a vector digested with the EcoRI, and
XhoI restriction enzymes. The digestion was conducted by incubating 5 µg plasmid
(pcDNA 3.1(+) for the “Kozak” cloning, and pEGFP-C1 for the Q68 cloning), CutSmart,
40 U XhoI, and 40 U EcoRI, for 1.5 h at 37℃.
A fusion of the vector and purified PCR product was then conducted by mixing 80 ng
vector, 60 ng purified PCR product, and 0.2 (v/v) Fusion Enzyme mix; and incubating for
15 min at 50℃. The fusion product was then transformed as in section 4.3.
4.2.3 Site-Directed mutagenesis
SDM was used to introduce mutations to DNA. Two SDM’s were conducted during this
thesis; the introduction of restriction sites, and a Kozak sequence to the start of a p110β
sequence with primers “Forward EcoRI pcDNA p110β”, and “Reverse EcoRI pcDNA
p110β”; and the introduction of the 15 bp insert predicted to be part of Q68 by the
“Forward Q68 Insert”, and “Reverse Q68 Insert” (Table 3.8). The PCR solution contained
10 ng plasmid template, 0.2 µM forward, and reverse primer (Table 3.6), 2.5% DMSO, 2.5
mM MgCl2, 2.5 mM dNTP, HF buffer, and 2 U polymerase (Phusion). The PCR was then
conducted as in table 4.4.
Table 4.4: Thermal program for SDM PCR.
Temperature (℃) Time (mm:ss) Cycles
1st Denature 95 0:30
Denature 95 0:30
Anneal Tm 1:00 ×25
Extension 68 1:00 pr kBp
Last extension 68 7:00
Hold 10 ∞
10-20 U of DpnI was added to the PCR product, and incubated for 1 h, at 37℃) in order to
digest methylated DNA, i.e. non-PCR product. The digested product was then
transformed as in section 4.3.
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4.2.4 Sequencing
DNA samples were sequenced using the BigDye v.3.1 protocol. PCR was conducted with
DNA sample as shown in table 4.6, with 0.1 (v/v) Big Dye solution, 0.1 (v/v) Sequencing
buffer, and 0.01 (v/v) sequencing primer (Table 3.6), and run as described in table 4.5.
Samples were then delivered to the sequencing facility to be sequenced.
Table 4.5: Thermal program for sequencing PCR.
Temperature (℃) Time (mm:ss) Cycles
1st Denature 98 5:00
Denature 98 0:10
Anneal 55 0:05 ×30
Extension 60 4:00
Hold 10 ∞
Table 4.6: Amount (ng) of DNA template used during sequencing PCR.









Transformation was done in order to create a large copy number of target DNA sequence.
2.7 µl DNA was added to 50 µl cells and mixed by pipetting once. The cells were then
incubated on ice for 30 min, followed by heat-shock at 42℃ for 45 seconds. The cells were
then immediately transferred to ice and incubated for 2 min. Cells were subsequently
incubated for 1 h at 37℃, and 250 rpm after adding 80 µl Super Optimal Broth (SOC)
medium (Table 3.1.2). The cells were then plated to an appropriate antibiotic containing 10
cm agar plate and incubated upside down overnight, at 37℃. The plates were stored at 4℃.
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4.4 Inoculation
Four colonies were picked from the agar plate and grown in 5 ml LB-medium (Table 3.1.2)
with appropriate antibiotics at 37℃ at 250 rpm overnight. The samples were then
centrifuged at 5 200 ×g for 15 min at 4℃. The pellet was then collected, and Mini-prep was
conducted as described in the “Nucleospinr Plasmid/Plasmid No Lid” protocol.
4.5 Agarose gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments based on their size. 1–2%
agarose was added to Tris-acetate-EDTA (40mM Tris, 20mM Acetate, and 1mM
Ethylenediaminetetraacetic acid (EDTA)) (TAE Buffer), and brought into solution by
boiling. 0.5 µg/ml ethidium bromide (EtBr) was added and mixed. The gel was then cast
at room temperature in a gel casting kit with a comb. The electrophoresis was run in a gel
electrophoresis block with the gel submerged in TAE Buffer, at 100V. The gel was then
imaged using a Gel Doc™ EZ (Table 3.5).
4.5.1 Agarose gel extraction
DNA Bands from agarose gels were extracted and purified following the protocol by
Macherey-Nagel with their NucleoSpinr Gel and PCR Clean-up (5.2) protocol (Table: 3.7).
4.6 Protein concentration determination
The concentration of protein solutions were determined by bicinchoninic acid assay (BCA).
4 µl protein sample and 4 µl of BCA standard mix (0.0, 0.5, 1.25, 2.5, 5.0 µg/ml) were
pipetted in triplicate to a 96 well plate. Bovine serum albumin (BSA) and protein were
diluted in the same buffer. 200 µl of BCA Protein Assay Reagent mix (50:1 Pierce™ BCA
Protein Assay Reagent A, Pierce™ BCA Protein Assay Reagent B) was then pipetted onto
each of the loaded wells, then incubated for 10 min at 37 ℃. The absorbance was
subsequently read at 562 nm with an Epoch™ Microplate Spectrophotometer.
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4.7 SDS-PAGE
Protein samples were separated based on molecular weight by using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A protein is denatured, given a
negative charge, and subjected to an electrical field. The applied field migrates proteins
towards the positive anode at different rates, where smaller proteins migrate faster than
larger proteins.
SDS gels were made with 10% acrylamide/bisacrylamide (37.5:1) at 1.5 mm thickness
(Table 3.1.3). Protein samples were mixed with Laemli sample buffer (Table 3.1.3). Samples
were boiled at 100 ℃ for 5 min and kept on ice until loaded into the gel. Electrophoresis
was conducted at 100 V. The gel was then used for western immunoblotting.
4.8 Western immunoblotting
Proteins were visualised by transferring them from an SDS gel onto a nitrocellulose
membrane at 200 V for 2h in ice, or at 20-50 V O/N at 4 ℃ in transfer buffer (Table 3.1.3).
The membrane was washed 4×5 min with TBS-T (Table 3.1.3) afterwards, then blocked
with 7% Milk in TBS-T for 1h on a shaker. Diluted milk was washed away by 2x rinses
using TBS-T, before adding the primary antibody (Table 3.2), and incubating for 2 h on a
shaker at RT or O/N on a shaker at 4℃. Afterwards, blots were washed 4×5 min using
TBS-T on a shaker, and the secondary antibody was then added (Table 3.2) and incubated
for 1 h at RT on a shaker. Blots were then again washed 4×5 min with TBS-T. Blots were
visualised by first treating them with enhanced chemiluminescent (ECL) of either Pico or
Femto variant (Table 3.7), depending on band strength. A Bio-Rad CheiDoc™ XRS+
System (Table 3.5) was used for imaging.
After visualising the primary probe, the loading quality was then assessed. First, the blots
were stripped by incubating them with stripping buffer for 7 min at 37℃. The blots were
then blocked again with 7% milk in TBS-T for 1h on a shaker. Diluted milk was washed
away by 2x rinses using TBS-T, before adding lamin A/C (Table 3.2), and incubating for 2
h on a shaker at RT or O/N on a shaker at 4℃. Afterwards, blots were washed 4×5 min
using TBS-T on a shaker, and the secondary antibody was then added (Table 3.2) and
incubated for 1 h at RT on a shaker. Blots were then again washed 4×5 min with TBS-T,
and imaged, as above. The blot was then stripped, blocked, incubated with the primary
antibody α-tubulin (Table 3.2), washed, and imaged as above.
If visualisation with these antibodies did not work, ponceau (0.1% (w/v) in 5% acetic acid,
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0.5 g ponceau S, 250 ml acetic acid) was used, instead. Blots were washed 2× with TBS-T,
before adding ponceau and incubating for 30 min on a shaker at RT. Afterwards, blots were
washed 4×5 min using TBS-T on a shaker and imaged.
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5 Results
p110β has been detected in not only the cytoplasm but also in the nucleus of
non-transformed cell lines (Kumar et al. 2011). Our group has also detected p110β in both
cytoplasmic, and nuclear fractions from several endometrial cancer cell lines, including
RL95-2, and MFE-319 (Gavgani, Karlsson, et al. 2019). Our laboratory has tested for
p110β localisation using two different antibodies, one N-terminal (Santa Cruz, from AA
2-31) (Gavgani, Karlsson, et al. 2019), the other more C-terminal (Abcam, from AA
400-500) (unpublished data). These antibodies showed different resolving patterns, with the
C-terminus antibody showing additional lower bands. We attempted to validate these
findings by using a different set of antibodies, the same Santa Cruz, and a more C-terminal
antibody (Thermo Fisher, AA: 411-605).
5.1 Two antibodies against p110β show dissimilar resolving
pattern
We decided to probe whole, cytoplasmic, and nuclear fractions with two different
anti-p110β antibodies, one from Santa Cruz, and the other from Thermo Fisher (Table:
3.2), that recognises the area in p110β as shown in figure 5.1, in order to observe the
different resolving pattern. Fractions were obtained as discussed under section 4.1.7 and
4.1.8, then resolved by SDS-PAGE, before they were probed using the two different




Figure 5.1: RL95-2 cell fractions probed with p110β antibodies showing the
differing resolving pattern. Proteins obtained from whole (100 µg), cytoplasmic (50 µg),
and nuclear extract (30 µg) from RL95-2 were resolved with SDS-PAGE, then transferred
onto a nitrocellulose membrane. *The band above α-tubulin in the nuclear fractions are
from residual lamin A/C staining that was not stripped completely. A) One membrane was
then western blotted with Thermo Fisher anti-p110β (#703364). Lamin A/C and
α-tubulin were then used to verify loading purity for nuclear and cytosolic fraction,
respectively. B) Another membrane was western blotted with a Santa Cruz anti-p110β
(#376641). Lamin A/C and α-tubulin were then used to verify loading purity for nuclear
and cytosolic fraction, respectively. C) Depicted model of the canonical p110β form.
Binding sites in regards to amino acid number, and location for the epitopes of the Santa
Cruz, Thermo Fisher, and Abcam antibodies are shown. Abbreviations: ABD - Adaptor
Binding Domain, RBD - Ras Binding Domain.
100 µg whole cell extract, 50 µg, cytosolic, and 30 µg nuclear fraction were loaded in order
to compensate for varying concentrations of p110β within each fraction.
The Thermo Fisher antibody binds to amino acids number 411 until 605 (PIK3CB
Antibody (703364) 2020), as seen in figure 5.1 C), and showed two bands around the 100
kDa marker; one above, one underneath, in both whole, and cytosolic fractions. Our group
have observed this pattern before; the band above 100 kDa marker has always been present
when probing with anti p110β antibodies and is consistent with the canonical form of
p110β. The lower band has only been observed for some antibodies, in some cell lines
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(Gavgani, Karlsson, et al. 2019, and Kumar et al. 2011)). What this lower band indicates is
so far unknown. Meanwhile, a stronger band resolved above the 50 kDa marker in both the
whole and nuclear fraction (Figure 5.1 A).
The antibody supplied by Santa Cruz binds to amino acids number 2 until 31 (PI 3-kinase
p110β Antibody (C-8) 2020) (Figure 5.1 C). Probing with this antibody showed a band
above 100 in all of the samples, but a weaker band in the nuclear fraction. The antibody
also detected bands above 50 kDa in both the whole and cytosolic fractions. There were
also a detectable band at the same resolving height in the nuclear fraction, albeit much
weaker (Figure 5.1 B). The bands at around 50 kDa migrated lower for the Thermo Fisher
antibody compared to Santa Cruz. This matches an observation made earlier by our group
when probing with both of these antibodies on the same blot (non-published data).
The purity of each fraction was confirmed by probing with antibodies against proteins that
are located in distinct fractions, and are ubiquitously expressed. Lamin A/C is located
within the nuclear lamina (Gerace, Blum, and Blobel 1978), and antibodies against Lamin
A/C will therefore only stain fractions containing this nuclear protein. Figure 5.1 show
Lamin in both whole, and nuclear, but no bands in cytosolic fraction for both
antibody-blots. An antibody against α-Tubulin, a 50 kDa mass protein was used to show
purity in regards to cytoplasmic fraction, as it is not found within the nucleus. Figure 5.1
show α-tubulin in both whole, and cytoplasmic fractions.
5.2 The predicted Q68 isoform is expressed in RL95-2 cells
The results shown in figure 5.1 suggests the possible presence of a p110β isoform with a
mass of about 50 kDa. Candidates that would fit the lower p110β band in figure 5.1 was
searched for on Ensemble. At the time of writing there were five sequences predicted to
produce novel proteins, listed as “protein coding biotypes” 1. Out of these, two entries were
seen as possible candidates for the observed lower band in figure 5.1 A). The most likely
candidate was a sequence with UniProt code “Q68DL0” (PIK3CB - Phosphatidylinositol
4,5-bisphosphate 3-kinase catalytic subunit beta isoform - Homo sapiens (Human) -
PIK3CB gene & protein 2020) henceforth referred to as “Q68”. Q68 had a predicted mass
of 59,770 Da. It was also the only sequence (besides the canonical form) with a transcript
support level (TSL) Category one 1 (Appendix, figure 6.1). The other candidate: H0Y871
was deemed a less plausible candidate because of its lower TSL score of 2, its mass was also
more dissimilar to the resolved bands in figure 5.1 A), at a theoretical mass of 80.5 kDa.
1Defined on ensambl as: Gene/transcipt that contains an open reading frame (ORF).
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TSL is calculated by comparing mRNA, and expressed sequence tag (EST) alignments to
GENCODE transcripts. For sequences with a TSL category of 1: “all splice junctions of the
transcript are supported by at least one non-suspect mRNA” 2 (Transcript flags 2020, and
Gene: PIK3CB - Ensembl 2020).
Q68 was predicted to start at the ATG codon from base pair 1663-1665, located inside the
helical domain of canonical p110β. Both the canonical and the predicted shortform share
the same stop codon. Q68 was predicted to contain an insertion of 15 bases compared to
the canonical p110β inside the catalytic domain. This insert is identical to 15 base pairs of
the intron upstream of canonical exon 17 (Figure 5.2 A) . Three primers (7495, 7591, and
8001; Table 3.6) were designed to align to the Q68 insert (Figure 5.2 B), to test for the
possible isoform’s presence at the mRNA level and then used in an RT-PCR against
RL95-2 RNA extract.
To test for the possible isoform’s presence at the mRNA level, three primers (7495, 7591,
and 8001; were designed to align to this insert as seen in figure ), and used in a RT-PCR
against RL95-2 RNA extract.
2Suspect mRNA is defined by Ensembl as “Erroneous transcripts and libraries identified in lists maintained




Figure 5.2: RT-PCR on predicted Q68 insert produced DNA band of predicted
length. A) Model of both the canonical p110β and the predicted shortform Q68
(Q68DL0). Amino acid changes from the predicted insert of Q68 highlighted in red (DDL
−→ DVCFPLDL). B) Forward primers designed against the Q68 insertion, located within
the canonical intron 17. Three primers were designed to amplify the DNA sequence,
including the insert found in the predicted Q68 inform from cDNA. The insert sequence is
marked in red. C) 1% agarose gel of PCR product of cDNA with three forward primers
(7495, 7591, and 8001) targeting the Q68 insert, and the reverse sequencing primer (Table
3.8). The PCR products were then run through a 1% agarose gel to separate the PCR
products based on size, using ethidium bromide for staining. The resulting gel was then
imaged using a Gel Doc™ EZ.
The resulting PCR products were separated by use of agarose electrophoresis (Figure 5.2
C)). Although the successful PCR should resolve one band at about 250 bp, both primer
7495, and 7591 unexpectedly resolved into two bands correlating at 400 bp, with 7592,
resolving an additional band at 500 bp. Meanwhile, primer 8001 had one band, correlating
in between the 300, and 200 bp marker. All of the bands were extracted and then
sequenced, as PCR of the insert had proven difficult.
Sequencing of the 400 bp, PCR products obtained from the “ 7495” primer, and the 500 bp
“7591” primer gave sequences that aligned with “Pan paniscus DEAD-box helicase 3
X-linked (DDX3X), transcript variant X3, mRNA”, using blast. The 400 bp band for the
“7591” primer gave no sequence product. Of note, none of the primers, when blasted with
Primer-Blast from the national center of biotechnology information (NHI) during primer
design, aligned to the “Pan paniscus DEAD-box”. The band from primer “8001” gave a
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sequence aligning to Q68’s theoretical sequence, including its insert, and 200 bp
downstream, as seen in figure 5.3.
The sequence obtained from the PCR product using primer 8001, aligned with the
predicted insert, and downstream bases of the Q68 isoform, as seen in figure 5.3. The
alignment between the Q68 theoretical sequence and sequence result from primer 8001 is
shown in figure 5.3 A. The insert is highlighted red, with the sequencing histogram over the
insert area shown in figure 5.3 B). In summary, the RL95-2 cells are likely to express the
predicted Q68 isoform at the mRNA level.
A
B
Figure 5.3: RL95-2 cell expressed the Q68 isoform. A) The cDNA obtained from
RL95-2 cells was used in RT-PCR with a primer targeting the insert within Q68. The
reverse primer was located about 200 bp downstream. The PCR product was subsequently
sequenced, using the same reverse primer. The alignment between the theoretical Q68 DNA
sequence (“Q68”), and the PCR product sequence (“8001”) is depicted in 5′ to 3′ direction.
Matches between each sequence are denoted by a (|), and mismatches are denoted by (-).
B) The histogram obtained by sequencing, shows the area covering the insert, and
downstream sequence. Each base pair’s relative signal strength is denoted by the height
along the y-axis of each coloured line. Adenine (A) is denoted by green, thymine (T) by
red, cytosine (C) by blue, and guanine (G) by black.
5.3 p110β and Q68 have different Kozak sequence strengths.
In order to further test the transnational ability of Q68, we needed to construct further
experiments; during this, the PIK3CB gene was analysed.
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A possible Kozak sequence was found during the analysis for the possible isoform Q68.
Kozak sequences are conserved sequences surrounding the start codon (AUG) in mRNA
and facilitate translation. While a Kozak sequence is not necessary for translation, stronger
Kozak sequences are often tied to higher expression of genes. The most typical Kozak
sequence is: CCA
G
CCATGGGC, with the underlined bases being the most conserved
(Kozak 1989). Both the canonical p110β and Q68 isoforms contain a Kozak sequence, with
the canonical being; TTATGAATGTG; and Q68 isoform being: AATGAAATGGA. The
canonical form p110β only contain secondary Kozak sequence bases. The Q68 contains the
two most conserved bases, -3, G; and +1, G. Thus the Q68 may contain a stronger Kozak
sequence, leading possible independent translation.
5.4 HeLa cells express low levels of canonical p110β
In order to test the transnational ability of Q68, we constructed two experiments; the first
would mutate the ATG’s of the p110β isoforms, and observe the transnational differences
between the mutants. The other experiment was an overexpression quantification
experiment. In order to conduct theses experiments, we would needed a model cell line
containing low levels of expressed p110β, and the possible Q68 isoform. So that most of the
expressed p110β and Q68 would be from the transfection.
The levels of p110β was tested for in the cell lines HEK, and HeLa; These cell lines have
already observed to naturally express lower levels of p110β when compared to RL95-2 cells
by our lab. We extracted whole cell extract from HEK and HeLa cells as in section 4.1.7.
70 µg of each fraction were separated based on size using SDS-PAGE, then transferred to a
nitrocellulose membrane to probe with the Thermo Fisher anti-p110β antibody. The
α-tubulin antibody was used as a marker for equal loading between the wells.
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Figure 5.4: p110β levels in, HEK, and HeLa cell lines, observed by western
immunoblotting with anti-p110β of whole cell extract. The proteins (70 µg)
obtained from whole cell extract from HEK or HeLa cells were resolved with SDS-PAGE,
and then transferred onto a nitrocellulose membrane. The membrane was then probed with
a Thermo Fisher anti-p110β antibody. α- tubulin, was then used to verify equal loading
(Table 3.2).
Each of the cell line extracts showed a band correlating above the 100 kDa marker
consistent with the canonical isoform. The HeLa cells fraction contained an additional
band, correlating bellow the 100 kDa marker. This is consistent with previous blots made
by our group using HeLa, and the Thermo Fisher antibody. Another band correlated above
the 50 kDa marker. This band may correspond to the Q68 isoform, but it is also possible to
be a degradation product of canonical p110β.
We chose to use HeLa for our experiments, as they proved more amenable during
transfection, even though neither of these lines were optimal, in regards to p110β vs Q68
levels.
5.5 Mutation of ATG of short isoform Q68 may halt its
translation
A proof for the existence of the Q68 isoform would be to show that the resolving pattern
would change based on isoform knockout. If we were to knock out the canonical p110β, one
would expect no band above 100 kDa, while keeping the band above 50 kDa when staining
with the Thermo Fisher antip110β antibody. Inversely, knockout of Q68’s ATG should
result in the opposite effect.
A WT of p110β missing the pre-ATG Kozak sequence had its Kozak sequence
re-introduced, (section 4.2.2), using the primers “Forward / Reverse EcoRI pcDNA p110β”
(Table 3.6). This was then fused into a pcDNA 3.1(+) vector (Table 3.8) (Section 4.2.2).
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Two mutants were created from this vector, each with either the canonical p110β’s or Q68’s
start-codon mutated to AAC. This was done by SDM using either the ”Forward / Reverse
1st ATG knockout”, or with ”Forward / Reverse 2nd ATG knockout” primers (Table 3.6).
The success of each of these mutations was confirmed by sequencing.
HeLa cells were then subjected to transfection using either the WT ATG p110β (WT ATG
p110β), Kozak p110β with the canonical ATG mutated (1st ATG mutant), or with Kozak
p110β with the Q68’s ATG mutated (2nd ATG mutant) as described in section 4.1.5. A
control group was also run with no plasmid added during transfection. After 24 h
transfection whole cell extract was collected, and proteins were resolved by SDS-PAGE and
transferred to a nitrocellulose membrane for probing. The loading quality was confirmed
with ponceau. While lamin A/C or α tubulin would have been preferable control probes, as
these give a specific signal to either the nucleus or the cytoplasm, imaging of these did not
work.
All of the samples contained a band above the 100 kDa marker, with the WT p110β
sample’s 100 kDa band being slightly higher. The transfected samples contain a band
correlating underneath the 75 kDa marker, with the cell extract obtained from transfection
with ”Kozak p110β 2nd” primer having a stronger band. Sample 1,3, and 4 contained a
band above the 50 kDa marker, possibly corresponding to the Q68 isoform.
The blot points to the fact that our transfection was not entirely successful, as the band
strengths are similar for all wells, when one would expect the control to have a weaker
signal. Besides, while we do observe a reduction in the canonical signal in the 1st ATG





Figure 5.5: p110β translation levels visualized by western blot, using Thermo
Fisher anti-p110β. A) Diagram of the Kozak of the three different constructs. B) HeLa
cells were transfected with three p110β mutants: p110β containing its Kozak sequence,
canonical ATG mutated to AAC, or Q68 ATG mutated to AAC. Proteins were then
obtained by whole cell extract and separated based on size with SDS-PAGE. 23.1 µg
protein was loaded, then transferred onto a nitrocellulose membrane. The membrane was
then probed with a Thermo Fisher anti-p110β. Ponceau was used to verify the loading
volume equality.
5.6 Quantification of expressed phenotypes for p110β, and its
possible shortform Q68, when overexpressed.
With western blots hinting at a possible nuclear localisation of Q68 (Figure 5.1) we wanted
to determine, and quantify the localisation of the Q68 isoform within the cell, in
comparison to the canonical p110β form.
An open reading frame (ORF) sequence of p110β and Q68 were cloned into pEGFP-C2-,
and pEGFO-C1 vectors as in section 4.2.2, to generate the fusion protein with the tag in
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the N-terminus 3. The transfections were conducted on HeLa cells grown in 6-well plates, as
described under section 4.1.5. A control group was also run each time in parallel, were
HeLa cells were transfected with an empty EGFP construct. The cells were then fixated
and imaged as described under 4.1.6 before being counted manually.
In total, five patterns were observed, with the pattern of nuclear preference being exclusive
to the control group. The observed patterns during cell counting were “continuous”,
“nuclear preference”, “cytoplasmic preference”, “small vacuoles”, and “large vacuoles”.
Cells showing an even distribution of EGFP signal over the entire cell was labelled as
having a continuous pattern. Cells, where the EGFP signal was stronger within the nucleus
were counted as having a “nuclear preference”. In contrast, cells that had a stronger signal
in the cytoplasm were counted as “cytoplasmic preference”. A subset of cells with
cytoplasmic preference contained what appeared to be small vacuoles; these were counted
as having a “small vacuoles” pattern. Lastly, a small number of cells contained EGFP
signal in larger vacuoles; these were counted as having the “large vacuoles” pattern.
Examples for each of these patterns are shown in figure (Fig 5.6).
3Different vectors were used because the pEGFP-C2-p110β was already made before this thesis began.
When we then created the EGFP-Q68 we were out of pEGFP-C2 vector, the discrepancy was judged as
tolerable.
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Figure 5.6: Localisation patterns observed during cell counting. HeLa cells were
transfected with empty-EGFP, EGFP-p110β, or EGFP-Q68 containing plasmid (Table
3.8), then fixated, and labelled with DAPI, as a nuclear marker. Images were taken with a
Leica DMI6000 B microscope (Table 3.5) at 1000× magnification. The five distinct
phenotypes observed during cell counting are shown row by row, with the DAPI shown in
the first, EGFP in the second, and the merge in the third column.
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60% of the control cells showed an even distribution of EGFP in the cytoplasm, and
nucleus, with the remaining EGFP expressing cells showing a nuclear preference for EGFP.
Examples of these patterns are shown in figure 5.6, with the distribution shown in figure 5.7
B).
For the cells expressing EGFP-p110β, 50% showed an even distribution of EGFP signal
within the cell (figure 5.7 A)). The second most observed pattern, at 29.8% (±7.6%) had a
cytoplasmic preference for p110β. Two other patterns were observed for these cells, the
largest population with 12.9% (±3.5%) had a pattern reminiscent of autophagy, with small
cytoplasmic vacuoles. A similar pattern has been observed previously for p110β (Dou,
Chattopadhyay, et al. 2010). The smallest population, with 7.4% (±3.7%), was similar,
except that the observed vacuoles were significantly larger. Examples of each observed
phenotype, are shown in figure 5.6, with the distribution shown in figure 5.7 B) with red
bars.
For the Q68-EGFP, the largest population showed the small vacuoles, with 62.8% (±9.3%)
of the observed cells having this pattern (5.7 B)). When compared to the EGFP-p110β
transfected cells, about half as many, with 25.6% (±6.8%), had an even distribution of
EGFP over the entire cell. With only 4.1% (±1.9%) showing a cytoplasmic preference. The
percentage of cells showing the pattern were protein were aggregating to larger vacuoles was
very similar to EGFP-p110β, with 7.4 % (±0.6%). Examples of each observed pattern, are
shown in figure 5.6, with the distribution shown in figure 5.7 with yellow bars. If the small
vacuoles are indeed indicative of autophagy activity, then it would seem that the shortform





























































Figure 5.7: p110β has a continuous domain pattern, while Q68 is cytoplasmic with
intense small vacuoles dominant localisation pattern. HeLa cells were transfected with
EGFP as control, with EGFP-p110β, or EGFP-Q68. Cells were transfected for 24 h. The cells
were then fixed, and stained with DAPI, as a nuclear marker. Images were taken with a Leica
DMI6000 B microscope (Table 3.5) at 1000× magnification. Approximately 200 cells were imaged
of each condition, in two transfections. A) The dominant pattern observed for EGFP-p110β, and
EGFP-Q68 are shown. C) The quantification of the five distinct patterns observed during cell
counting is shown in the graph. With the percentage of EGFP-positive cells expressing each
pattern shown on the y-axis. The blue columns are cells transfected with EGFP, with the red
and yellow columns representing cells transfected with p110β, and Q68 tagged with EGFP.
Bars along the y-axis denote the standard deviation.
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6 Discussion
The PI3K pathway is a complex interconnected reaction matrix, with extensive research
conducted upon it. While much research has already been done, more still, remains to be
uncovered about this pathway. Most research conducted upon the ubiquitously expressed
Class I PI3Ks has been on p110α leaving the p110β PI3K as less understood. Our group,
while working on other studies, found inconsistencies between experimental, and theoretical
p110β resolving patterns in western blots. Discovering, and possibly explaining this
inconsistency became the focus of this thesis.
During our work, it became more and more plausible that the theoretical isoform of p110β
presented in Ensembl as “Q68DL0” correlated with the 50 kDa band observed in Thermo
Fisher probed Western blots. Indeed it was found to be expressed in RL95-2 cells, at the
mRNA level. It was also shown that the Q68 isoform contains a stronger Kozak sequence
when compared to the canonical ATG. But other experiments we attempted have not been
able to prove its existence as of yet.
6.1 Q68 may be a new short isoform of p110β translated from an
alternative ATG.
The possibility of an alternative isoform for p110β was hinted at by the two antibodies,
from Santa Cruz, and Thermo Fisher, and their differing western blot resolving patterns
detected in whole, cytoplasmic, and nuclear fractions.
The most noticeable difference between the two anti-p110β antibodies was how the lower
band, above 50 kDa, had apparent differing localization based on which antibody was used
with the Thermo Fisher giving no signal in the cytoplasmic fraction, but a strong signal in
the nuclear. While the Santa Cruz antibody gave a signal in the cytoplasmic fraction, but
no such signal in the nuclear fraction.
Upon closer inspection, the 50 kDa band found in the Thermo Fisher blot in figure 5.1, is
slightly lower than the Santa Cruz 50 kDa band, an observation made more evident by
another member of our lab (non-published data). A possible explanation for this is that
what we observe as the 50 kDa bands in these two blots maybe two different polypeptides;
be that different degradation product(s), or possible isoform(s). If indeed the Q68 isoform
exists then one would not expect the anti-p110β antibody from Santa Cruz to be able to
bind to it, as its binding site (from AA: 2-31) is not present in the theoretical Q68. While
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the antibody from Thermo Fisher may be able to bind to it, as parts of its binding site
(from AA: 411-605)) is in the theoretical Q68 isoform (Figure 5.1). Still, it was not unlikely
that both of these amino acid chains are degradation products, as p110β is an unstable
protein, and may rapidly degrade when not stabilised by either its regulatory subunit or an
N-terminal tag (Backer 2011).
The Q68 theoretical isoform was selected for further study as the most likely isoform to
correlate with the 50 kDa band observed in figure 5.1 A). The expression of Q68 was tested
for by conducting an RT-PCR experiment using primers that would bind to an insert found
exclusively in the Q68 isoform. Designing a primer that would bind specifically to this
insert turned out to be a challenge. We originally only designed one primer: 7591 (Table
3.6). While there were some possible unspecific annealing targets found for it during design,
experimentally it did not bind to any of these targets in detectable levels. Two bands were
detected and found to have high sequence identity with an unspecific protein, instead of the
theoretical Q68 sequence.
Afterwards, we designed two new primers, trying to get a specific binding to the Q68 insert.
7495 was designed to anneal before, and in the entire insert, while 8001 was designed to
anneal to before and after the insert. 7495 was also found to align with the same unspecific
sequence as 7591 did, while 8001 only produced a sequence covering the Q68 insert, and 200
bp downstream of it.
Being able to sequence out the Q68 insert from RL95-2 cDNA, strongly suggests that Q68
is indeed expressed in WT cells, at least for RL95-2 cells. As this experiment was only
conducted on RL95-2 cells, it remains to be seen if Q68 is expressed in other cell lines, or
for that matter in living organisms. As far as we know, this isoform has not been
characterised before, but further validation experiments are required.
Still, there is president for isoforms originating from downstream ATG’s (dATG) (). It has
also been shown that dATG’s are more likely to be expressed in genes where the start ATG
is located within a “suboptimal context”, such as a weak Kozak sequence. Also, genes with
suboptimal start ATG, and more optimal dATG’ were found to contain longer 5′ UTRs,
fitting the long 5′ UTR in PIK3CB (355 bp) (Bazykin and Kochetov 2011). Most isoforms
starting from dATG do so within the first 50 codons, a gene starting 555 codons
downstream is, as far as we know, undocumented.
We therefore, wanted to test if the Q68 isoform is translated from its predicted ATG site at
AA 555 in p110β. This was tested for by conducting an experiment where either the
canonical p110β or the theoretical Q68 isoform, had their ATG’s mutated to AAC. If Q68
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is expressed by the suspected ATG, then the band above 50 kDa should disappear only
when this ATG is mutated. Another group have also used this method for the SPG4 gene,
encoding spastin. This gene also contained a poor Kozak sequence at the start ATG, with a
stronger Kozak at the dATG (Claudiani et al. 2005).
How successful we were at this experiment is arguable. While we did observe a similar
pattern between the non-transfected sample, and the earlier probe on HeLa in figure 5.4
(Without the band bellow 100 kDa). The observations in the remaining samples were
perplexing. While it is tempting to conclude the transfection itself a failure, there are some
aspects that show that some transfection did take place. We have no reason to believe that
the mutations were faulty as all of the mutations were confirmed by sequencing.
The most apparent oddity is that the bands we expected to be stronger in the transfection
samples (above 100, and 50 kDa), are of the same intensity as the non-transfected sample.
The transfected WT, even has a weaker band above 50 kDa, when compared to the control.
The next point is that both of the ATG mutants contained a band that we did not expect.
The sample with the canonical ATG mutated still contains a band above 100 kDa. It is
weaker than the 100 kDa bands in either WT and second ATG mutant, suggesting that this
transfection did work to some extent. In any case, the Q68 ATG mutant sample is a bigger
mystery. First: it contained a band at the Q68 location. Second: a band we have observed
before (between 50, and 75 kDa), but not discussed, became stronger compared to the other
samples. A similarly located band can also be observed in the nuclear load in figure 5.1 A,
and in the whole fraction probed for both HEK and HeLa cell lines in figure 5.4.
A challenge during this experiment was that we could not check the transfection before
probing on the western blot. This took us more time, and as a result,we had less time to
perfect the protocols, and improve the transfection conditions.
So then what might have happened? Our main hypothesis to explain the weak transfection
is that the transfection was not allowed to take place over a long enough time.
All in all, this experiment was only conducted once due to time constraints, and no honest
conclusion can be extrapolated without conducting more transfections, and perfecting the
protocol until repeatable transfection can be done.
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6.2 Q68 is not nuclear, when overexpressed, with a bulky
N-terminal tag.
Canonical p110β has already been shown to localize in the nucleus (Marqués et al. 2009).
Our group has also previously found evidence of co-localization between p110β, and the
nucleolus in several cell lines, including RL95-2, and AU565 cells (Gavgani, Morovicz, et al.
2020, and Karlsson et al. 2016). The nucleolus has been shown to, among other functions,
produce most of the ribosomes within the cell (Derenzini, Montanaro, and Trerè 2017),
making it vital for protein translation, and therefore cell proliferation. Nucleolar
hypertrophy was even for some time considered as a diagnostic for malignancy; a theory
that was discarded in the 20th century as normal cells undergoing cell proliferation was also
found to exhibit nucleolar hypertrophy (Derenzini, Montanaro, and Trerè 2017). With the
possible discovery of a new p110β isoform, the possibility of showing nucleolar localisation
drove us to conduct a transfection experiment to show the localisation of overexpressed
EGFP-tagged isoforms. The western blot in figure 5.1 A) showed nuclear localisation of the
Thermo Fisher antibody target. We hypothesised that we would observe at least nuclear
localisation for Q68, if not nucleolar. HeLa cells were transfected with canonical p110β,
and shortform Q68 both tagged with EGFP on their N-terminus and made to overexpress
these fusion proteins. The p110β was tagged at its N-terminus side specifically, as p110β is
stabilised by bulky tags on the N-terminus (Backer 2011). We observed no nuclear, or
nucleolar localisation for either the canonical or the Q68 isoform within the counted HeLa
cells. Canonical p110β has been observed not to be transported to the nucleus when
overexpressed (Kumar et al. 2011), and as such, the cytoplasmic localisation was expected
for this form.
In contrast, our hypothesis for overexpressed Q68 placed its localisation within the nucleus.
We expected this because of the probing with the Thermo Fisher p110β antibody showed
nuclear localisation of the suspected Q68 band in figure 5.1 A). Our hypothesis was; that
since Q68 can most likely not bind to the regulatory subunit p85 (at least as well as the
canonical), as it does not contain the ABD domain, and it does not contain the suspected
NLS (Kumar et al. 2011). That there would be other mechanisms separate from the
canonical p110β’s that would take over and shuttle the protein into the nucleus. Moreover,
if this was the case, then we hoped that the Q68 would not have a similar overexpression
pattern as the canonical p110β form. A possible explanation for the discrepancy is that
EGFP is too big of a tag, changing the total mass of Q68 from 59.7 kDa to 86.6. Some
proteins with mass less than approximately 50 kDa have been found to be shuttled into the
nucleus without having an NLS or being reliant on co-transport (Cooper 2000). Tagging
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Q68 with EGFP may have been enough to stop the transport of Q68 into the nucleus. In
any case, Q68 can not translocate to the nucleus by itself, when overexpressed, and tagged
to EGFP.
The use of a FLAG-tag may solve this problem, and should be considered for future
experiments. FLAG-tags are polypeptide tags that can be fused our protein. These tags
consist of a short specific polypeptide chain “DYKDDDDK” (Hopp et al. 1988), and would
therefore not disturb the mass of Q68 to such an extent as EGFP does. A possible problem
with this is that the stability of p110α is dependant on binding to either a regulatory
subunit or on its fusion to a bulky N-terminal tag. The extent to stabilisation is also linear
with the bulk of the N-terminal tag, with more bulky tags leading to higher stabilisation
(Yu et al. 1998). We would expect p110β also exhibit this instability as the protein is
structurally similar to p110α. The stabilising effect on p110β of FLAG would be lower
when compared to EGFP. An alternative solution would be to incubate the cells at a lower
temperature such as 30℃; this temperature has been shown to imitate the stabilising effect
of the regulatory subunit on p110α (Yu et al. 1998). This may induce a change in
expression in the cells due to stress. Another solution would be to tag p110β with a bulky
N-terminal tag and fuse the flag tag at the C-terminus instead, stabilizing the protein,
while still allowing detection by FLAG. Lastly, the regulatory subunit could be
overexpressed at the same time, and act to stabilize p110β.
6.3 Q68 may have a stronger connection to autophagy than
p110β, in HeLa cells
The dominant pattern we did observe for Q68 was a strong tendency to segregate to
apparent small vacuoles reminiscent of the pattern observed for p110β when active in
autophagy (Dou, Chattopadhyay, et al. 2010, and Dou, Pan, et al. 2013). These vacuoles
appeared as small specs, distributed evenly within the cytoplasm. It is possible that Q68
functions much the same as the canonical p110β is hypothesised to do. As discussed earlier,
the canonical p110β has been observed to have a possible regulatory role for autophagy,
allowing multicellular organisms to initiate autophagy by limiting growth signals, instead of
just being initiated by limited nutrient availability (Dou, Pan, et al. 2013).
The binding between p110β and Rab5 has been found to be reliant on two amino acids,
Q596, and I597S (Dou, Pan, et al. 2013). Q68 contains these amino acids, and it is,
therefore, possible that Q68 can also bind to Rab5, and act as a scaffolding protein as
p110β does.
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The strong correlation between Q68, and the apparent autophagy pattern, hints at a
possible function for this isoform as autophagy initiating/promoting molecule.
A problem with this hypothesis is that, as mentioned, the autophagy role ofp110β is
controversial (Bresnick and Backer 2019). One of the controversial points is that Rab5, is
expressed at 150 times more, then p110β in vivo (Schwanhäusser et al. 2011), making it
unlikely that p110β can function on Rab5, in a discernible manner. The same argument can
also be used for Q68, to a more significant effect even. While we have not quantified the
expression levels of Q68, the weaker bands, and general difficulty of detecting this isoform
are good indicators that the short isoform, is expressed at lower levels then canonical p110β.
6.4 Which band does represent Q68?
The band briefly touched on in the previous section, the one sometimes found above what
we believe to be Q68, and bellow the 75 kDa marker, has made us unsure if we have
constituted as the Q68, is the Q68 band. For one Q68, has a theoretical mass of 59’770 Da.
It might be that the band above 50 kDa found during probing using the Thermo Fisher
antibody is too low to represent the Q68 isoform, and instead, the higher is representative
of Q68.
This theory is supported by the pattern shown by the WT p110β Kozak in figure 5.1,
where the band above 50 kDa is not visible, while the band bellow 75 kDa is. If the band
bellow 75 kDa represents Q68, then that would mean that the overexpression made it
visible. Contradicting this observation is the fact that the band bellow 75 kDa is equally
strong in the WT, as in the Q68 ATG mutant samples in figure 5.5. If there was a mix up
during loading of the ATG mutants, and the actual samples are opposite, i.e. “1st ATG
mutant” is the “2nd ATG mutant”, and inversely for the other mutant. Then the bellow 75
kDa band may represent the Q68 isoform. Otherwise, it becomes unlikely. We find the
possibility of a mix up as unlikely, but not impossible. Due to time constrains two, people
handled the mutant during SDM, and a mix-up might have happened at some point during
this process. Sequencing the samples, and clearing the possibility of this error should be
done before repeating the experiment. The possibility of the bellow 75 kDa band being the
Q68 is also supported for in figure 4.1 A, where a befitting band can be observed in the
nuclear sample. Inversely, this band can also be a degradation product of canonical p110β.
That becomes more visible when the canonical form is overexpressed.
The band bellow 75 kDa may also be explained by another dATG. Three in-frame codons
are possible candidates at AA-444 (ATACGATGGTT), 472 (AAGAAATGTTG), and 476
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(ATCCAATGGGA). On the basis on matching the band observed bellow 75kDa the codons
at AA-472, and 476 fit best based on mass, with theoretical masses of 69.1 kDa, and 68.6
kDa. That said the dATG at AA-444 contains the strongest Kozak signal
(CCA
G
CCATGGGC), containing both the -3 and +1 most conserved bases. The other two
codons are only surrounded by one of these conserved bases. By surveying the data-set
collected by (Philippon, Brochier-Armanet, and Perrière 2015), it was found that all of
these dATGs have conserved Kozak sequences in the PIK3CB gene over the entire Amniota
clade. Of the conserved dATGs the AA-444, and AA-472 were also found to be conserved
in all of the species of the Osteichthyes clade. Q68’s theoretical ATG is conserved for all of
the members in the Amniota clade. One outlier was the Latimeria chalumnae (Philippon,
Brochier-Armanet, and Perrière 2015). This may be indicative of the importance of the
Kozak sequence for one of these ATG’s. Of note is all of the dATG’s are found within the
helical domain, which itself is conserved (Philippon, Brochier-Armanet, and Perrière 2015).
The conservation of the dATG’s may therefore be a consequence of the helical domain, not
the Q68 expression.
In conclusion, our findings establish the novel ”Q68” sequence as a possible p110β isoform,
based on detecting a specific mRNA sequence, and describing an alternative start codon
surrounded by a strong Kozak sequence. These preliminary findings motivate further
studies into the possible existence, and function of this elusive protein. The discovery of an
alternative p110β isoform may explain some aspects of p110β which are currently not
known, or not understood well. For example, the possible correlation between p110β and
autophagy. Future experiments might include alternative overexpression experiments, in
order to solve the apparent localisation discrepancy between Western blot probing, and
overexpression by transfection. Solving the ATG mutation experiment could also elucidate
the uncertainty of the alternative ATG.
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Harvesting cells for RNA isolation was generally done in 1× 15 cm plate of 80% confluent
cells. When different culture plates were used, volumes were adjusted proportionally. Media
was removed, and cells were washed once with PBS before completely trypsinizing and
collecting into a tube. This was followed by centrifuging at 70 ×g for 5 min and kept on ice.
Media was removed, and the pellet was carefully washed with 5 mL PBS and centrifuged at
300 ×g for 5 min at 4℃. The cell pellet was resuspended in 1 mL of PBS, and centrifuged
at 300 ×g for 5 min at 4℃. PBS was discarded, and the previous centrifugation step was
repeated, but for 1 min to remove excess PBS. The pellet was carefully resuspended in 1
mL TRI reagent (TRI Reagentr, Sigma-Aldrich, T9424), and incubated at RT for 5-10
min, and frozen at -80℃ until needed.
For RNA isolation, all steps were performed at RT, unless otherwise specified. Cells
resuspended in TRI reagent were thawed, to which 200 µl chloroform was added. The
contents were vortexed for 1 min, then again for 30 sec, before being incubated for 1 min
and centrifuged at 12’000 ×g for 15 min at 4℃. The top layer was transferred and placed
on ice, to which 500 µl phenol chloroform isoamyl alcohol mixture was added on ice.
Contents were vortexed for 1 min and incubated for 2 min, then centrifuged at 12’000 ×g
for 10 min at 4℃. Again, the top layer was transferred on ice, and 500 µl chloroform was
added, vortexed for 1 min and incubated for 1 min, then centrifuged at 12’000 ×g for 10
min at 4℃. Top phase was collected on ice, and 20 µg of RNA grade glycogen was added
along with 500 µl isopropanol, before vortexing for 10 sec, and incubating for 20-30min.
After incubation, the solution was centrifuged at 13’000 ×g for 20 min at 4℃, and
supernatant was discarded. Pellet was resuspended in 1 mL ice-cold 70% ethanol, vortexed
for 30 sec, and centrifuged at 8000 ×g for 5 min at 4℃. Supernatant was discarded, and
pellet was spun down at 8000 ×g for 5 min at 4℃ to remove any ethanol. RNase free water
was added to the pellet (volume depending on pellet size), and vortexed for 5 sec every 5
min for 20 min. RNA concentration was measured in an Epoch microplate
Spectrophotometer, and total RNA was stored in -80℃ until needed.
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6.6 cDNA synthesis
1 µg of total RNA was used to produce 50 ng/µl cDNA with random primers according to
the protocol given in the High-Capacity cDNA Reverse Transcription Kit. Transcribed
cDNA was stored at -20℃ until real-time PCR (RT-PCR) was run.
6.7 TSL score
Figure 6.1: Screenshot of ensambl page for the PIK3CB gene showing only the
canonical (P42338), and the Q68DL0 forms with a TSL score of 1.
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